Oncocyte(OCX) - 2025 Q4 - Annual Results

Exhibit 99.1 IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results NASHVILLE, TN., March 26, 2026 — Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow shareholders, We are pleased to share that GraftAssureDx has become, to our knowledge, the first ever kitted dd-cfDNA assay to be submitted to the FDA for regulatory review. Our FDA submission this week represents the culmination ...